UNPA’s Israelsen: ‘We’ve really got to get this NDI issue resolved’

Under DSHEA, a manufacturer of a New Dietary Ingredient—i.e., one that was not marketed as a dietary ingredient prior to Oct. 15, 1994—is required to file a notification with FDA 75 days before putting the ingredient on the market. The dossier is supposed to provide scientific backing to prove that the ingredient can be "reasonably expected to be safe" under the conditions of use. Within that time frame, FDA is supposed to respond with a letter either concurring with the assertion of safety or raising objections. (FDA never puts itself in the position of "approving" ingredients.) First issued in 2011 , the initial NDI draft guidance was met with significant industry backlash , which led to the Agency to go back to the drawing board. Five years later, a revised draft guidance was released . That revised version was described as “more positive than negative” by Steve Mister , president and CEO of the Council for Responsible Nutrition, when it was released in 2016, but some stakeholders still voiced concerns that the Agency’s approach would dampen innovation . Since that time, the Agency has adopted more of a piecemeal approach to the NDIN guidance, stating that it is working “expeditiously” to finalize sections as and where it can. The FDA recently finalized Section V (“NDI Notification Procedures and Timeframes”) of the NDI guidance, which focuses on frequently asked questions about the NDIN submission and review process. Industry reaction was mixed, but most saw the announcement as progress and an important first step. “It’s good to have anything,” Israelsen told NutraIngredients-USA. “It’s been a long time. And this is the appetizer, all the meaty parts are yet to come. “It was a restatement in more clear terms with a couple of templates that people could use, so it’s an indication of progress and also, I think, a thoughtful process that they [FDA] are going through. The obvious question is, how soon can we expect the next pieces and the hard parts?” A FDA spokesperson told NutraIngredients-USA earlier this month that the Agency does not have an anticipated timeline for other parts of the guidance but said that it is "prioritizing finalization of additional sections as the Agency completes its review and analysis in light of competing priorities." Thirty years… One industry source told us this week that he thinks the industry will not have to wait too long for additional sections to be finalized over the course of 2024, and Israelsen said the whole NDI issue needs to be resolved. “I don’t think FDA can expect the industry to increase notifications until there’s clarity of process and agreement on some of the fundamentals,” he told us during the recent Expo West in Anaheim. “I am really hopeful we get there. We need to get over this. [It’s been] 30 years [since the passage of DSHEA]. We need to move on. “I would encourage FDA to move along as quickly as they can. I do understand they are resource constrained, terribly, but given how important they feel this is and we think it is, it needs to move on.” DSHEA Summit Israelsen also discussed the upcoming DSHEA Summit , hosted by NutraIngredients-USA and supported by UNPA, that will bring together the architects of the law, key industry stakeholders and former and current FDA officials to discuss the past, present and future of the U.S. dietary supplements industry. The DSHEA Summit will take place at the Hyatt Regency, Salt Lake City on Monday, June 10, 2024, from 8:30 a.m to 2 p.m. Confirmed speakers include:

UNPA’s Israelsen: ‘We’ve really got to get this NDI issue resolved’

Related Topics

FDA’s 2025 legislative wish list calls for mandatory supplement product listing

UNPA's reflections on 2023: The year of opposite choices

Announcing the DSHEA Summit: A landmark event bringing together the architects of the law & leading industry voices